Progressive apoptosis in the dopaminergic neurons of substantia nigra lead to Parkinson’s disease. Since neurons require substantially higher supply of energy, their mitochondria have a pivotal status in neuronal survival. These organelles have a key role to play in apoptosis and any impairment thereof may lead to apoptosis mediated cell death.
Objectives:
To evaluate and compare the mitochondrial membrane potential (Δψ) in Parkinson’s disease patients and healthy controls.
Methods:
We evaluated the mitochondrial membrane potential (Δψ) in the peripheral blood mononuclear cells by Flow cytometry using a lipophillic cationic dye JC-1 in Parkinson’s disease patients (N = 61) and healthy controls (N = 37).
Results:
JC-1 fluorescence was measured and represented as percentage positivity i.e., Mean±SEM in FL-2 (representing non-apoptotic aggregates) and FL-1 (indicating apoptotic cell population having depolarized or damaged mitochondria) channels. The ratio of % FL-2 and % FL-1, which is an indicator of cellular mitochondrial membrane potential, was found to be significantly higher in healthy controls (Mean±SEM = 60.48±18.42) as compared to patients (Mean±SEM = 24.30±4.671) in both stimulated and unstimulated conditions.
Conclusions:
Mitochondrial membrane potential is altered and hence its evaluation in peripheral blood mononuclear cells may serve as an early marker of apoptosis in PD and, therefore, may pave way for early interventions. Since Δψ has a role in the maintenance of electrochemical gradient, the disruption of which may lead to neuronal apoptosis, Δψ is intricately nested within etiopathogenesis of PD and may prove to be useful in design of diagnostics, prognostics and therapeutics for PD.
Arthur, J. Verhoeven., Verhaar, R., GouwerokE.G., de KorteD. (2005). The mitochondrial membrane potential in human platelets: A sensitive parameter for platelet quality. Transfusion, 45.
2.
Blandini, F., Nappi, G., Tassorelli, C., Martignoni, E. (2000). Functional changes of the basal ganglia circuitry in Parkinson’s disease. Progress in Neurobiology, 62(1), 63–88.
3.
Blum, D., Torch, S., Lambeng, N., Nissou, M., Benabid, A.L., Sadoul, R., Verna, J.M. (2001). Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson’s disease. Progress in Neurobiology, 65(2), 135–172.
4.
Borutaite, V. (2010). Mitochondria as decision-makers in cell death. Environmental and Molecular Mutagenesis, 51(5), 406–416.
5.
Brand, M.D., Chien, L.F., Ainscow, E.K., Rolfe, D.F., Porter, R.K. (1994). The causes and functions of mitochondrial proton leak. Biochimica et Biophysica Acta, 1187(2), 132–139.
6.
Cossarizza, A., Baccarani-Contri, M., Kalashnikova, G., Franceschi, C. (1993). A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cationic, 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochemical and Biophysical Research Communications, 197, 40–45.
7.
Darzynkiewicz, Z., Bedner, E., Smolewski, P. (2001). Flow cytometry in analysis of cell cycle and apoptosis. Seminars in Hematology, 38, 179–193.
8.
Gandhi, S., Wood-Kaczmar, A., Yao, Z., Plun-Favreau, H., Deas, E., Klupsch, K., Downward, J., Latchman, D.S., Tabrizi, S.J., Wood, N.W., Duchen, M.R., Abramov, A.Y. (2009). PINK1-Associated Parkinson’s Disease is caused by Neuronal Vulnerability to Calcium-Induced Cell Death. Molecular Cell, 33(5), 627–638.
9.
Ganguly, A., Basu, S., Chakraborty, P., Chatterjee, S., Sarkar, A., Chatterjee, M., Choudhuri, S.K. (2010). Targeting Mitochondrial Cell Death Pathway to Overcome Drug Resistance with a Newly Developed Iron Chelate. PLoS One, 5(6), 11253.
10.
Greenamyre, J.T., Sherer, T.B., Betarbet, R., Panov, A.V. (2001). Complex I and Parkinson’s disease. International Union of Biochemistry and Molecular Biology, 52(3–5), 135–141.
11.
Hauser, D.N., Hastings, T.G. (2013). Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism. Neurobiology of Disease, 51, 35–42.
12.
Höglinger, G.U., Carrard, G., Michel, P.P., Medja, F., Lombès, A., Ruberg, M., Friguet, B., Hirsch, E.C. (2003). Dysfunction of mitochondrial complex I and the proteasome: Interactions between two biochemical deficits in a cellular model of Parkinson’s disease. Journal of Neurochemistry, 86(5), 1297–1307.
13.
Hong, Z., Shi, M., Chung, K.A., Quinn, J.F., Peskind, E.R., Galasko, D., Jankovic, J., Zabetian, C.P., Leverenz, J.B., Baird, G., Montine, T.J., Hancock, A.M., Hwang, H., Pan, C., Bradner, J., Kang, U.J., Jensen, P.H., Zhang, J. (2010). DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain, 33, 713–726.
14.
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S.M., Ahmad, M., Alnemri, E.S., Wang, X. (1997). Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91(4), 479–489.
15.
Ly JenniferD., Grubb, D.R., Lawen, A. (2003). The mitochondrial membrane potential (Δψm) in apoptosis; an update. Apoptosis, 8(2), 115–128.
16.
Manna, A., Saha, P., Sarkar, A., Mukhopadhyay, D., Bauri, A.K., Kumar, D., Das, P., Chattopadhyay, S., Chatterjee, M. (2012). Malabaricone-A Induces A Redox Imbalance That Mediates Apoptosis in U937 Cell Line. PLoS One, (5), 36938.
17.
Mounsey, R.B., Teismann, P. (2011). Mitochondrial Dysfunction in Parkinson’s Disease: Pathogenesis and Neuroprotection. Parkinson’s Disease, 617472.
18.
Mollenhauer, B., Locascio, J.J., Schulz-Schaeffer, W., Sixel-Doring, F., Trenkwalder, C., Schlossmacher, M.G. (2011). Alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study. The Lancet Neurology, 10, 230–240.
19.
Novikova, L., Garris, B.L., Garris, D.R., Lau, Y.S. (2006). Early signs of neuronal apoptosis in the substantia nigra pars compof the progressive neurodegenerative mouse 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine/probenecid model of Parkinson’s disease. Neuroscience, 140(1), 67–76.
20.
Olanow, C.W., Tatton, W.G. (1999). Etiology and pathogenesis of Parkinson’s disease. The Annual Review of Neuroscience, 22, 123–144.
21.
Perier, C., Vila, M. (2012). Mitochondrial Biology and Parkinson’s Disease. Cold Spring Harbor Perspectives in Medicine, 2(2), a009332.
22.
Perier, C., Bové, J., Wu, D.C., Dehay, B., Choi, D.K., Jackson-Lewis, V., Rathke-Hartlieb, S., Bouillet, P., Strasser, A., Schulz, J.B., Przedborski, S., Vila, M. (2007). Two molecular pathways initiatemitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson’s disease. Proceedings of the National Academy of Sciences of the United States of America, 104(19), 8161–8166.
23.
Perier, C., Tieu, K., Guegan, C., Caspersen, C., Jackson-Lewis, V., Carelli, V., Martinuzzi, A., Hirano, M., Przedborski, S., Vila, M. (2005). Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proceedings of the National Academy of Sciences of the United States of America, 102(52), 19126–19131.
24.
Reers, M., Smiley, S.T., Mottola-Hartshorn, C., Chen, A., Lin, M., Chen, L.B. (1995). Mitochondrial membrane potential monitored by JC-1 dye. Methods in Enzymology, 260, 406–417.
25.
Rottenberg, H., Wu, S. (1998). Quantitative assay by flow cytometry of the mitochondrial membrane potential in intact cells. Biochimica et Biophysica Acta, 1404(3), 393–404.
26.
Sadek, H.L., Almohari, S.F., Renno, W.M. (2014). The Inflammatory Cytokines in the Pathogenesis of Parkinson’s Disease. Journal of Alzheimers Disease and Parkinsonism, 4, 148.
27.
Subramaniam, S.R., Chesselet, M.F. (2013). Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Progress in Neurobiology, 106-107, 17–32.
28.
Schuler, F., Casida, J.E. (2001). Functional coupling of PSST and ND1 subunits in NADH: Ubiquinone oxidoreductase established by photoaffinity labeling.Bioenergetics. Biochimicaet Biophysica Acta—Bioenergetics, 1506(1), 79–87.
29.
Scherzer, C.R., Eklund, A.C., Morse, L.J., Liao, Z., Locascio, J.J., Fefer, D., Schwarzschild, M.A., Schlossmacher, M.G., Hauser, M.A., Vance, J.M., Sudarsky, L.R., Standaert, D.G., Growdon, J.H., Jensen, R.V., Gullans, S.R. (2007). Molecular markers of early Parkinson’s disease based on gene expression in blood. Proceedings of the National Academy of Sciences of the United States of America, 104, 955–960.
30.
Sullivan, P.F., Fan, C., Perou, C.M. (2006). Evaluating the comparability of gene expression in blood and brain. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 141B, 261–268.
31.
Tokuda, T., Qureshi, M.M., Ardah, M.T., Varghese, S., Shehab, S.A., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., El-Agnaf, O.M. (2010). Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology, 75, 1766–1770.
32.
Vila, M., Jackson-Lewis, V., Vukosavic, S., Djaldetti, R., Liberatore, G., Offen, D., Korsmeyer, S.J., Przedborski, S. (2001). Bax ablation prevents dopaminergic neurodegeneration in the 1methyl-4-phenyl-1,2,3,6-tetrahydropyridinemouodel of Parkinson’s disease. Proceedings of the National Academy of Sciences of the United States of America, 98(5), 2837–2842.
33.
Winklhofer, K.F., Haass, C. (2010). Mitochondrial dysfunction in Parkinson’s disease. Biochimica et Biophysica Acta, 1802(1), 29–44.
